A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs Linsitinib (Primary) ; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions
- 01 Oct 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 09 May 2013 Planned End Date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov.
- 09 May 2013 Planned initiation date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.